Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -424K | 0 | -357K | 0 | 0 |
| Operating Income | -28M | -25M | -27M | -21M | -13M |
| EBITDA | -27M | -24M | -25M | -19M | -13M |
| Net Income | -27M | -23M | -26M | -14M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.15
+0.00% today
1Y Change
-8.73%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vivani Medical, Inc. (VANI) is a Healthcare stock with a market cap of $80.00M and listed on NASDAQ. The stock last traded around $1.15 and down 8.7% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow -19.4% with operating margin 0.0% and ROIC -79.7%. Stock Foundry combines VANI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VANI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VANI Max Drawdown
-49.84%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VANI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$12.8M
+8.0% YoY
Free Cash Flow
-$11.5M
+39.7% YoY
Revenue Growth
+0.0%
EPS Growth
+0.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -424K | 0 | -357K | 0 | 0 |
| Operating Income | -28M | -25M | -27M | -21M | -13M |
| EBITDA | -27M | -24M | -25M | -19M | -13M |
| Net Income | -27M | -23M | -26M | -14M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 16M | 18M | 21M | 45M | 2M |
| Total Assets | 39M | 42M | 46M | 51M | 5M |
| Total Liabilities | 24M | 24M | 25M | 7M | 3M |
| Shareholder Equity | 16M | 18M | 21M | 44M | 2M |
| Total Debt | 19M | 19M | 21M | 955K | 2M |
| Net Debt | 3M | 961K | 42K | -44M | -366K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
11M
+41.7% YoY
Capital Expenditures
572K
-69.2% YoY
Free Cash Flow
12M
+39.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-317.0%
Debt / Equity
1.20x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.